This course has been reviewed and updated since its original publication date of December 2015.
The Immuno-Oncology program is designed to help the busy clinician keep on top of the rapidly developing field of immunotherapy as it relates to oncology. The program address a wide variety of topics including cancer immunobiology, classes of agents, potential predictive biomarkers, clinical activity in the areas of melanoma and non-small cell lung cancer, response determination and the management of immune-related adverse events.
- Describe the components of the normal human immune system and their role in surveillance and anti-tumor activity
- Identify the mechanisms by which cancer vaccines may induce specific immunity to cancer
- Examine other potential biomarkers of benefit to immune checkpoint blockade
- Identify the immune modulating agents that have been used in the clinic
- Apply RECIST-based response assessments to patients receiving cancer immunotherapy in the clinic
- Describe management strategies for the toxicities associated with immunotherapies
Continuing Education Credit
8 Credits/Points are available for participation in this course. Certificate and credit types available include:
- AMA PRA Category 1 Credits™
- MOC Points:
ABIM MOC Points
ABMS (ABAI, ABPath, ABR, ABU) MOC Points
- CNE Contact Hours
- ONCC ILNA Points in Treatment Modalities and Symptom Management
- CPE Credits
- Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
- Certificate of Completion may be used to document participation, but no credit will be conferred.
- This course expires on May 18, 2020. Participants must complete all necessary course components by this date to receive credit.